SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

Ads

You May Also Like

Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results

Strategic Focus on Growing Global Vitaros® Revenue and Achieving Profitability in 2017Apricus Granted Type ...

Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock

ALPHARETTA, Ga., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical ...